Retrospective analysis of the second year of safety surveillance of the qdenga® (TAK-003) vaccine in private vaccination centers, including a sub-analysis of safety in adults over 60 years of age
Ongoing
The TAK-003 vaccine, Qdenga, developed by Takeda, was approved by ANMAT in April 2023 and has been available in Argentina since November 2023 for individuals aged 4 years and older, with no upper age limit. Clinical trials demonstrate that Qdenga has a favorable safety and immuno…
Sponsor: Fundación Vacunar
Last updated Sep 10, 2026 16:00 UTC